Literature DB >> 32241801

Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic.

Rosie Scuccimarri1, Evelyn Sutton2, Mary-Ann Fitzcharles3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32241801     DOI： 10.3899/jrheum.200369

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  7 in total

1.  Management strategies for patients with autoimmune diseases during the COVID-19 pandemic: A perspective from China.

Authors:  Yu Liu; Christopher Chang; Qianjin Lu
Journal:  Eur J Rheumatol       Date:  2020-04-10

2.  Rheumatologists' practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt.

Authors:  Tamer A Gheita; Mohamed N Salem; Nahla N Eesa; Noha M Khalil; Nada M Gamal; Rasha Abdel Noor; Abdel Hafeez Moshrif; Rawhya El Shereef; Faten Ismail; Nermeen Noshy; Rasha M Fawzy; Emad Elshebini; Iman Khalifa; Hanan El Saadany; Samar Tharwat; Amany El-Najjar; Yousra Abdel Fattah; Rehab Sallam; Amany S El-Bahnasawy; Ola Gharbia; Eman Hassan; Amira ElShanawany; Eman F Mohamed; Soha Senara; Mervat Ismail; Samah I Nasef; Ahmed M Abdalla; Dina Elessawi; Samar M Fawzy; Esam Abu Alfadl; Asmaa Khalifa; Nouran M Abaza
Journal:  Rheumatol Int       Date:  2020-07-24       Impact factor: 2.631

Review 3.  Implications of COVID-19 in pediatric rheumatology.

Authors:  Ezgi Deniz Batu; Seza Özen
Journal:  Rheumatol Int       Date:  2020-06-04       Impact factor: 2.631

4.  How the COVID-19 pandemic has influenced pediatric rheumatology practice: Results of a global, cross-sectional, online survey.

Authors:  Ezgi Deniz Batu; Lovro Lamot; Erdal Sag; Seza Ozen; Yosef Uziel
Journal:  Semin Arthritis Rheum       Date:  2020-09-28       Impact factor: 5.532

Review 5.  Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities.

Authors:  Milo Gatti; Fabrizio De Ponti
Journal:  Pharmaceutics       Date:  2021-02-25       Impact factor: 6.321

6.  Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19.

Authors:  Oya Koker; Fatma Gul Demirkan; Gulsah Kayaalp; Figen Cakmak; Ayse Tanatar; Serife Gul Karadag; Hafize Emine Sonmez; Rukiye Omeroglu; Nuray Aktay Ayaz
Journal:  Rheumatol Int       Date:  2020-08-02       Impact factor: 2.631

Review 7.  How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.

Authors:  Piercarlo Sarzi-Puttini; Daniela Marotto; Marco Antivalle; Fausto Salaffi; Fabiola Atzeni; Giovanni Maconi; Giovanni Monteleone; Giuliano Rizzardini; Spinello Antinori; Massimo Galli; Sandro Ardizzone
Journal:  Autoimmun Rev       Date:  2020-05-05       Impact factor: 9.754
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.